Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Common Equity (2019 - 2025)

Historic Common Equity for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $80.2 million.

  • aTYR PHARMA's Common Equity rose 2317.51% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year increase of 2317.51%. This contributed to the annual value of $70.0 million for FY2024, which is 2276.58% down from last year.
  • aTYR PHARMA's Common Equity amounted to $80.2 million in Q3 2025, which was up 2317.51% from $74.8 million recorded in Q2 2025.
  • aTYR PHARMA's Common Equity's 5-year high stood at $117.4 million during Q3 2021, with a 5-year trough of $40.8 million in Q2 2021.
  • Over the past 5 years, aTYR PHARMA's median Common Equity value was $81.4 million (recorded in 2024), while the average stood at $83.5 million.
  • Per our database at Business Quant, aTYR PHARMA's Common Equity skyrocketed by 26515.97% in 2021 and then crashed by 3467.73% in 2022.
  • aTYR PHARMA's Common Equity (Quarter) stood at $109.1 million in 2021, then tumbled by 34.68% to $71.3 million in 2022, then rose by 27.18% to $90.7 million in 2023, then decreased by 22.77% to $70.0 million in 2024, then grew by 14.59% to $80.2 million in 2025.
  • Its Common Equity was $80.2 million in Q3 2025, compared to $74.8 million in Q2 2025 and $75.0 million in Q1 2025.